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Short course adjuvant terlipressin in acute variceal bleeding:
A randomized double blind dummy controlled trial
Zahid Azam1,2, Saeed Hamid1,⇑, Wasim Jafri1, Mohammad Salih1, Zaigham Abbas1,
Shahab Abid1, Hasnain Shah1
1

Section of Gastroenterology, Department of Medicine, The Aga Khan University, Karachi, Pakistan; 2National Institute of Liver
& Gastro-intestinal Diseases (NILGID), Dow University of Health Sciences, Karachi, Pakistan

Background & Aims: Terlipressin is recommended for 3–5 days
as adjuvant to endoscopic variceal band ligation (EVBL) in esophageal variceal bleeding (EVB). We assessed whether terlipressin
can be administered for a shorter period of time to patients with
EVB.
Methods: All eligible EVB patients received 24 h of open label
terlipressin at presentation. After successful EVBL, patients were
randomized to receive active or dummy terlipressin for the next
48 h. We excluded patients with failure to achieve initial hemostasis, bleeding gastric varices, known hepatoma, and/or portal
vein thrombosis, advanced cirrhosis (Child-Pugh score P12),
and patients on a ventilator. The primary outcome was failure
to control EVB. The secondary outcomes were 30-day mortality;
re-bleeding and composite outcome of failure to control EVB.
Results: A total of 130 eligible patients were randomized to
receive terlipressin for a total of 24 (short course or SC) or 72 h
(usual course or UC). Baseline patient characteristics were comparable; the majority of patients were HCV-infected and male.
There was one failure to control EVB (1.5%) in UC and none in
SC terlipressin (p = 0.50). The 30-day re-bleeding rate was 1.5%
and 3.1% in UC, and SC terlipressin, respectively (p = 0.50). The
30-day mortality was 12, 6 (9.2%) patients in each group
(p = 0.50). The 30-day failure to control bleeding was observed
in 14 patients; seven in each group (p = 0.494).
Conclusions: In patients with esophageal variceal bleeding, a 24h course of terlipressin is as effective as a 72-h course when used
as an adjunctive therapy to successful EVBL.
Ó 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
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BCU, bleeding care unit; Hb, hemoglobin; ITT, intention to treat; CI, conﬁdence
interval; IHD, ischemic heart disease; CPS, Child-Pugh Score.

Introduction
Bleeding from gastro-esophageal varices is an important and
severe complication of progressive liver disease. Varices are identiﬁed in about 30% of patients with compensated cirrhosis and
60% of patients with de-compensated cirrhosis [1]. Esophageal
variceal bleeding (EVB) occurs in 10–20% of cirrhotic patients
per year and each bleeding episode can be associated with inhospital mortality [2]. EVB remains the major cause of death in
these patients, although the mortality has decreased substantially in the last 20 years [3–4]. Currently, the keystone of therapy
of acute EVB is endoscopic variceal band ligation (EVBL). In addition, vasoactive agents like terlipressin, octreotide, vapreotide or
somatostatin are recommended to be started as adjunctive therapy [5] and found to be highly effective in the management of
these patients. Furthermore, these vasoactive drugs are recommended to be continued for 72–120 h (3–5 days) by various
guidelines, including Baveno IV [5], as the risk of re-bleeding is
considered to be the highest in the ﬁrst 5 days of index bleed [6].
The use of terlipressin as an adjunctive therapy has received
recent attention, and was found to be associated with survival
beneﬁts in a meta-analysis compared with the endoscopic intervention alone or other vasoactive agents [7–9]. In a randomized
controlled trial from our group reported earlier [10], terlipressin
was found to be of comparable efﬁcacy to octreotide, along with
endoscopic intervention, for the control of variceal bleeding.
Although recommended for 3–5 days, the optimal duration of
vasoactive drug use in an individual patient remains an unsettled
question. One reason may be that these drugs have not been well
studied in clinical situations for a short duration, especially
when the risk of re-bleeding could be considered to be low. For
example, patients with active bleeding at endoscopy or failure
to control initial hemostasis, portal vein thrombosis (PVT), hepatocellular carcinoma (HCC), high bilirubin levels, high Child-Pugh
score are considered at high risk for poor outcome for re-bleeding
and mortality [2] compared to patients where these factors are
not present. In our clinical practice, we have observed that shortening the duration of terlipressin to 24 h in selected patients with
variceal bleeding, in which good hemostasis had been achieved
with EVBL, did not adversely affect clinical outcomes [11]. Therefore, in the present study, we have prospectively tested the
hypothesis that 24 h of terlipressin treatment (short course or
SC) is non-inferior to 72 h of terlipressin treatment (usual course
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or UC) in EVB patients after successful EVBL. If proven correct,
this could have important implications on the cost of managing
acute variceal bleeding and may also decrease the side effects
of therapy.

Materials and methods
Study design
From August 2006 until September 2008, we conducted an investigator initiated
randomized, double blind, dummy controlled trial of short vs. usual course of terlipressin as an adjuvant to EBVL in patients presenting with EVB, in our center.
The study was approved by the Ethical Review Committee (ERC) of our university;
an informed consent was obtained from each study subject or his/her next of kin,
in case the study subject was incompetent to give consent, and the study was
conducted following the Good Clinical Practice (GCP) guidelines. An independent
data safety monitoring board monitored the trial and had access to non-blinded
data, and the study protocol was registered at www.clinicaltrials.gov (ClinicalTrials.gov identiﬁer: NCT00369694).
Study patients
The study subjects were adult cirrhotic patients presenting to the emergency room
(ER) with a history of hematemesis (frank blood or coffee ground emesis) and/or
melena (black tarry stools). They were either known cirrhotics or, in some patients,
cirrhosis was diagnosed on the basis of clinical examination, laboratory investigation results, and/or ultrasonography. Esophageal variceal bleeding was diagnosed
if, at endoscopy, active bleeding was seen from a varix or patients presented with
red color signs on their esophageal varices with blood in the esophagus or stomach
and no other potential site of bleeding was identiﬁed. In the presence of both gastric
varix (GV) and esophageal varices (EV), EVB was considered if EV were large
(P5 mm in diameter), no other cause of acute bleeding was identiﬁed and no stigmata of recent bleeding were noted on GV (red sign or a punctum).
We excluded patients who were potentially at high risk of re-bleeding,
deﬁned as initial failure to control EVB with EVBL, the presence of known HCC
or any other hepatic metastatic malignancy and/or PVT [12–13], advanced cirrhosis (Child-Pugh score P12), presence of sepsis and/or multi-organ failure requiring continuous ionotropic and/or ventilatory support after ﬂuid and blood
product resuscitation, and bleeding disorders. We also excluded patients with
active angina or dynamic ECG changes (ST segment depression or elevation
P2 mm) precluding the use of terlipressin, GV bleeding, pregnant females, and
those who refused to give consent.
Study treatment
Patients suspected to have EVB were potential study subjects; open label terlipressin (NovapressinÒ Curatis Pharma GmbH, Hannover, Germany and marketed
by BF Biosciences/Ferozsons laboratories) was started at the emergency room as a
bolus of 2 mg and then 1 mg was administered every 6 h, for the initial 24 h. All
patients were managed in the bleeding control unit (BCU), with continuous noninvasive cardiac and hemodynamic monitoring including cardiac rhythm, pulse
rate, blood pressure, and oxygen saturation. Hemoglobin (Hb) was checked every
6 h for the initial 48 h and then every 12 h till discharge. Likewise, serum creatinine was checked daily. Packed red blood cells were transfused to maintain target Hb of P8 g/dl. Patients were started on IV omeprazole 40 mg qd and switched
to oral preparation once able to tolerate orally, after EVBL [14]. All patients
received prophylactic intravenous ceftriaxone 2 g daily for three days; antibiotics
were stopped if there was no other indication to continue [15].
Endoscopic variceal band ligation was performed in all patients within 12 h of
admission, using the Saeed Six Shooter Multi-Band LigatorÒ (Wilson-Cook Medical, North Carolina, USA) attached to a video endoscope (Olympus GIF H-180,
Tokyo, Japan). Attending gastroenterologists with at least 5 years of experience
performed all EVBL.
After conﬁrmation of EVB and successful initial hemostasis with emergency
EVBL, patients were randomly assigned to continuation of terlipressin, either as
SC or UC therapy, administered in a double blind dummy controlled fashion.
The allocation of drug assignment was done by a pharmacist using computer generated simple random sequence at the central pharmacy of the hospital. Therefore, during the initial 24 h of admission, terlipressin was dispensed to both
groups as an open label drug from the pharmacy. Subsequently, those random-
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ized to the 72-h group (UC regimen), after the initial 24 h of open label drug,
received ‘‘active terlipressin’’ at a dose of 1 mg every 6 h for the following 48 h,
in a 5 ml pre-ﬁlled syringe. On the other hand, patients randomized to the 24-h
arm (SC), after the initial 24 h of open label terlipressin, received the ‘‘terlipressin
dummy’’ containing 5% dextrose water administered every 6-h intervals for the
following 48 h, in a 5 ml pre-ﬁlled syringe. Case report forms were ﬁlled daily
and blood requirement, adverse events and the criteria to characterize failure
to control EVB or any evidence of re-bleeding were noted.
All patients were kept at the hospital for at least 4 days from the index bleed
and were then considered discharged if no other reason was observed to keep
them at the hospital. At discharge, all patients were started on propranolol if
there was no contraindication. They were given instructions to report to ER if they
noticed any melena or hemetemesis. All patients discharged at day 4 were contacted by phone at day 5, to assess failure to control EVB. Patients were seen
15 and 30 days after the index bleed to assess secondary outcomes. If a patient
missed a follow-up appointment, they were contacted by phone to ascertain
the secondary outcomes.
Endpoints
The primary endpoint was efﬁcacy of SC to prevent failure to control EVB; failure
to control EVB was deﬁned according to the Baveno IV consensus conference
guidelines [5]. According to Baveno IV, the time frame for the failure to control
bleeding is any re-bleeding within 120 h (5 days). The criteria deﬁning ‘‘failure
to control EVB’’ were; either fresh hematemesis P2 h after start of a speciﬁc drug
treatment or therapeutic endoscopy, aspiration of greater than 100 ml of fresh
blood in patients who had a naso-gastric tube in place; a P3 g drop in Hb if no
transfusion was administered, or death within 5 days. The secondary outcomes
were 30-day mortality, 30-day re-bleeding deﬁned as occurrence of new hematemesis or melena after a period of 120 h (5 days) attributable to esophageal varices, and 30-day composite outcome (re-bleed or death). All patients were
followed for 30 days as per initial protocol but data was available for 45-day follow-up, which was not different than 30 days secondary outcomes.
Statistical analysis
We postulated that 24 h of terlipressin treatment is non-inferior to 72 h of therapy for the control of EVB. The latter regimen has been shown to reduce re-bleeding rate from 30% to 15% [16]. To demonstrate this, a sample size of 65 for the
experimental group (24 h terlipressin) and 65 for the standard group (72 h terlipressin) was calculated to achieve 80% power at a 5% signiﬁcance level, using a
one-sided equivalence test of proportions when the proportion in the standard
group is 12% and the proportion in the experimental group being tested for equivalence is 12%, and the maximum allowable difference between these proportions
that still results in equivalence (the range of equivalence) is 15%.
All patients who had been randomly assigned to a treatment group were
included in the intention-to-treat (ITT) analyses. Results are expressed as
mean ± standard deviation, median with ranges for all continuous variables and
numbers (percentage) for categorical data. Univariate analysis was performed
using the independent Student’s t-test for continuous variables, and Pearson Chisquare test or Fisher exact tests were applied wherever appropriate. For the assessment of outcome measures all p-values were one-sided. Kaplan–Meier survival
curves were plotted and mean bleed free survival with conﬁdence intervals (CI)
were reported using log-rank test to assess the difference in the 30-day re-bleeding,
30-day mortality and 30-day failure to control EVB (composite outcome).

Results
Study patients and study drugs
During the study period, a total of 267 cirrhotic patients with
hematemesis and/or melena were admitted. Twenty-six patients
were excluded due to ischemic heart disease and were managed
with adjuvant octreotide infusion. The remaining 241 patients
were started on terlipressin immediately at the time of admission
from the emergency room. One hundred and eleven patients
were excluded from the trial after initial endoscopy as they did
not meet the enrolment criteria, were considered high risk variceal bleeders or refused to give consent for the trial (Fig 1).
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Cirrhotic and suspected EVB
n = 267

Suspected EVB and started on
terlipressin
n = 241

Terlipressin not given and
excluded due to IHD
n = 26

Excluded, n = 111
• High risk for re-bleed, n = 67
1. Failed to achieve initial hemostasis, n = 5
2. Hemophilia, n = 1
3. Known HCC, n = 41
4. Known PVT, n = 1
5. SIRS, n = 8
6. Advanced cirrhosis (CPS ≥12), n = 8
7. HRS, n = 3
• Bleeding from source other then EVB, n = 32
1. Ulcer bleed, n = 20
2. Gastric varix bleed, n = 12
• Refused to participate, n = 12

Final randomization
(EGD confirmed EVB)
n = 130

72 h terlipressin
(group A)
n = 65

24 h terlipressin
(group B)
n = 65

Completed terlipressin 72 h (n = 63)
Consent withdrawal after 48 h (n = 1)
Terlipressin stopped after 24 h due to
cardiac ischemia and later, death (n = 1)

Completed 24 h terlipressin
n = 65

Control of EVB
(ITT analysis)
n = 64

Failed to control EVB
(ITT analysis)
n=1

Control of EVB
(ITT analysis)
n = 65

Failed to control EVB
(ITT analysis)
n=0

Fig. 1. Flow chart of study algorithm, enrolment, and randomization.

Finally, 65 patients were randomized to each group to receive a
total of either 72 h (UC) or 24 h (SC) of terlipressin therapy. The
two groups were not signiﬁcantly different in their baseline characteristics; the study subjects were predominantly male and HCV
was the major etiology for liver cirrhosis in both groups (Table 1).
Efﬁcacy of the 24-h terlipressin regimen
The primary outcome was assessed for variceal re-bleeding in the
initial 120 h (5 days), as deﬁned by the Baveno IV guidelines
[5,17]. There was only one failure to control EVB observed in
the 72 h (UC regimen) and none in the 24 h of terlipressin regimen. This failure was due to the death of the patient on day 4,
due to myocardial infarction. Hence on ITT, there was no signiﬁcant difference in the 72-h (UC) as compared to the 24-h (SC)
treatment for the control of EVB, p = 0.50 (Fisher exact test; 1sided).
For the assessment of secondary outcomes, the study subjects
were followed for 30 days from the index bleed (Table 2 and
Fig. 2). One patient in the 72-h terlipressin group and two
patients in the 24-h group had a re-bleeding within 30 days
(p = 0.50 Fisher exact test). The mean bleeding free survival was
29.8 days (CI: 29.5–30.1) and 29.5 days (CI: 28.8–30.2) in the
72- and 24-h terlipressin group, respectively (p = 0.285, log-rank
test). The all cause 30-day mortality was 12, 6 patients, (9.2%) in
each group (p = 0.50, Pearson Chi-square test). The mean survival

was 28.4 days (CI: 27.1–29.7) and 28.2 days (CI: 26.8–29.6) in
72- and 24-h terlipressin group, respectively (p = 0.495, log-rank
test).
The composite outcome of 30-day failure to control EVB, i.e.
30 days re-bleeding and/or mortality, was observed in 14
patients, seven in each group. The mean bleeding free survival
was 28.3 days (CI: 26.9–29.6) and 28.1 days (CI: 26.6–29.5) in
UC and SC terlipressin, respectively (p = 0.494, log-rank test; 1sided). Hence, 24 h of terlipressin treatment was non-inferior to
72 h of terlipressin treatment for 30-day re-bleeding, mortality
and composite outcome of failure to control EVB, when plotted
on a survival curve (Table 2).
Safety of the 24-h terlipressin regimen
The failure to control EVB was also the safety measure for the
short course (24 h of terlipressin). As mentioned above, 24 h of
terlipressin treatment was non-inferior to 72 h terlipressin treatment for the control of EVB (p = 0.50, Fisher exact test; 1-sided)
and was considered safe.
There was only one patient in the UC who had no history of
ischemic heart disease (IHD) and a normal baseline ECG but later
developed ECG changes with a troponin leak after 24 h of terlipressin therapy. The patient was switched to IV octreotide and
died on day 4 of the index bleed due to myocardial infarction
and congestive cardiac failure. Another patient in the UC group,
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Table 1. Baseline patient characteristics of the 72- and 24-h terlipressin groups.

72 h terlipressin (n = 65)

24 h terlipressin (n = 65)

p values

Age (yr)

49.7 ± 12.1

49.8 ± 11.2

0.89

Gender (M)

49 (75.4%)

48 (73.8)

0.84

Hb at presentation (g/dl)

9.4 ± 2.3

9.4 ± 2.4

0.77

Platelets at presentation (x 106)

116.3 ± 45.8

115.9 ± 56.1

0.45

Systolic blood pressure (mmHg)

117.1 ± 23.9

115.0 ± 20.9

0.23

Characteristics

Pulse (beats/min)

95.3 ± 20.1

9.8 ± 17.45

0.15

Serum creatinine (mg/dl)

1.3 ± 1.6

1.1 ± 0.5

0.17

Serum albumin (g/dl)

2.5 ± 0.5

2.4 ± 0.4

0.35

Prothrombin time (sec)

18.5 ± 13.6

18.3 ± 9.2

0.70

Total bilirubin (mg/dl)

1.8 ± 1.3

1.9 ± 1.2

0.36

Child-Pugh score

8.4 ± 1.6

8.9 ± 1.7

0.52

Packed red cell transfusion (units)

1.2 ± 1.3

1.1 ± 1.0

0.17

Active bleed

15 (20.1%)

16 (24.6%)

0.84

Presence of ascites

23 (35.4%)

25 (38.5%)

0.13

6 (9.2%)
25 (38.5%)
34 (52.3%)

9 (13.8%)
25 (38.5%)
31 (47.7%)

7 (10.8%)
41 (63%)
17 (26.2%)

7 (10.8%)
30 (46.2%)
28 (43%)

33 (50.8%)
10 (15.4%)
7 (10.8%)
4 (6.2%)
11 (16.9%)

42 (64.6%)
6 (9.2%)
10 (15.4%)
3 (4.6%)
4 (6.2%)

Grade of varices
Grade II
Grade III
Grade IV
Child-Pugh Class
Child’s A
Child’s B
Child’s C
Etiology of cirrhosis
HCV
HBV
Cryptogenic
HBV + HCV
Alcoholic

0.69

0.11

0.19

in whom bleeding was controlled, developed hemorrhagic pancreatitis of unknown etiology at the time of discharge and died
on day 9 of index bleed. One diabetic patient in the 24-h terlipressin group developed acute stroke on day 6 after discharge, following completion of his trial dose. Causes of
death over 30-day follow-up and possible side effects are
shown in Table 3.

Discussion
The optimal duration of vasoactive drug treatment in bleeding
cirrhotic patients treated with endoscopic therapy is not known.
For the management of all patients with EVB, most guidelines,
including Baveno IV, [5,18] consider the treatment duration of
terlipressin as a minimum of 3 days (72 h). Our study shows that
24-h terlipressin treatment is non-inferior to 72-h terlipressin
treatment in acute EVB, as adjuvant therapy to successful EVBL.
As far as we know, we have demonstrated for the ﬁrst time, with
a double blind study, the efﬁcacy of ultra-short course (24 h) vs.
72 h of terlipressin treatment, as adjuvant therapy to endoscopic
variceal band ligation in acute variceal bleeding. This trial has
clinical implications of cost savings and may help shorten the
length of hospital stay in clinical practice and probably will be
associated with fewer side effects. On the basis of our previous
822

report [11] and the results of this trial, we may recommend
shortening the duration of therapy in future guidelines for the
management of EVB in acute EVB patients.
There have been other recent attempts of shortening the duration of terlipressin therapy but none has compared adjuvant therapy in each arm with shortening the duration of therapy. A
double blind, multi center randomized controlled trial reported
no signiﬁcant difference in the efﬁcacy to control variceal bleeding in a shorter course of therapy, i.e. 48 h of low dose of terlipressin (0.2 mg every 4 h) vs. 1 mg every 4 h, for 5 days [19].
Terlipressin was, however, used as monotherapy rather than as
an adjunct to EVBL, and perhaps because of these reasons the
30-day mortality was reported as 17.1% in the 48-h therapy
group and 20% in the 5-day therapy group [19]. In contrast, in
our trial, the 30-day mortality was 9.2% in both groups, this
was due to the fact that our study subjects comprised patients
in whom we had achieved initial hemostasis with EVBL. Patients
at high risk for re-bleeding were excluded and we used terlipressin as adjuvant therapy to EVBL, as recommended by most clinical guidelines.
In another recent study, 48 h of terlipressin (SC) treatment
along with EVBL, in low risk EVB patients, was compared with
terlipressin alone for 5 days [20]. This was a superiority trial comparing a shorter course of adjuvant terlipressin to the standard
5 days of terlipressin monotherapy and showed that even in
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Table 2. Secondary outcome measures.

72 h terlipressin

24 h terlipressin

p value

30 days re-bleed
(Mean days with 95% CI)
No. with proportion

29.8 (29.5-30.1)
1 (1.5%)

29.5 (28.8-30.2)
2 (3.1%)

0.285*
0.500†

30 days mortality
(Mean days with 95% CI)
No. with proportion

28.4 (27.1-29.7)
6 (9.2%)

28.2 (26.8-29.6)
6 (9.2%)

0.495*
0.500‡

Composite outcome (30 days failure to control EVB)
(Mean days with 95 % CI)
No. with proportion

28.4 (27.0-29.8)
7 (10.8%)

28.2 (26.7-29.7)
7 (10.8%)

0.495*
0.500‡

⁄

Log-rank test (1-sided).
Fisher exact test (1-sided).
Pearson’s Chi-square test (1-sided).

à

Table 3. Possible cause of the 30-day mortality and side effects.

A
Cause of death

Terlipressin
(UC) 72 h

(SC) 24 h

Myocardial infarction

1

0

Sepsis and SBP

2

1

Re-bleed

0

1

PSE and aspiration pneumonia

1

1

COPD exacerbation

0

1

Pancreatitis

1

0

Stroke

0

1

Duodenal ulcer bleed

1

0

Unknown (found dead)

0

1

B

Terlipressin

Adverse events (side effects)

(UC) 72 h

Myocardial infarction

1

(UC) 72 h
0

Pancreatitis

1

0

Stroke

0

1

low risk EVB, the combination of EVBL and terlipressin was superior to terlipressin alone. On the other hand, our trial was a noninferiority trial addressing a similar EVB patients’ group and we
could conﬁrm that the duration of adjuvant terlipressin therapy
could be ultra-shortened to 24 h and this was as effective as
the UC adjuvant terlipressin treatment.
High serum creatinine and bilirubin levels, and the presence
of encephalopathy are considered to be independent factors predictive of re-bleeding and mortality, as reported by D’Amico et al.
[2] and according to our own retrospective variceal bleeding data
base source analysis [21]. We therefore took the arbitrary cut off
of Child-Pugh score of 12 to cover these factors and deﬁned these
patients as high risk and excluded them from the trial. This most
likely explains the high success of EVB control in the current trial,
along with the fact that terlipressin was used as an adjuvant to
EVBL. Additionally, we believe that the high success rate achieved
with the treatment is partly due to the fact that we have included
in the trial only those patients in whom successful variceal band
ligation was performed and, immediately after endoscopy, we

randomized them to receive ultra-short course (total 24 h) vs.
usual course (total 72 h) of terlipressin.
Being a tertiary referral center, we may be experiencing a
referral bias towards patients who are able to reach our center
from various distances due perhaps to the fact that they may
have a high tendency to stop bleeding spontaneously. However,
we believe that this unexpected bias does not alter our study
results. There were 25% active bleeders in both groups (fresh
blood in naso-gastric tube or active esophageal spurting seen at
endoscopy) and 75% had melena at presentation but were not
actively bleeding, as shown in Table 1. Therefore, the number
of patients who were still actively bleeding at presentation and
in whom bleeding had stopped spontaneously was not different
between the two treatment arms.
In our hands, the overall safety of terlipressin was comparable
to that reported in other studies, as we encountered only one
patient who developed ECG changes and non-ST elevation, myocardial infarction and later died. One patient in the 72-h treatment regimen developed hemorrhagic pancreatitis on the day
of planned discharge and later died. The cause and effect relationship of terlipressin in causing ischemic pancreatitis remains
unclear to us and could well be a chance ﬁnding. No re-bleeding
was observed in both patients who died while in the trial, possibly due to terlipressin side effects.
We observed only one failure to control bleeding in the usual
course terlipressin on ITT, but none for the protocol analysis. This
low outcome was a limitation of the study design as our aim was
to assess the group with shorter duration where the patients had
achieved initial variceal bleeding control with EVB. Hence, our
results cannot be generalized to all EVB patients and are applicable to only EVB subjects achieving haemostasis with EVBL, in
whom we believe the duration of terlipressin therapy can be
safely and effectively shortened to 24 h only.
In conclusion, short course terlipressin as an adjuvant to EVBL
is as effective as UC for the control of EVB; all cause 30-day mortality, 30-day re-bleeding and composite outcome of 30-day failure to control EVB were not different when terlipressin was used
for 24 h in these patients. A larger population sample or metaanalysis studies are needed to better conﬁrm the present results.
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